Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hornet;
Enjoy your insight and wisdom.
Your posts frame the reasons why most of us are in the red and why the stock is close to its 52 week low.
Why did the company not demand better deals with their partners.
How far away do you think we are from euro approval?
With the most recent studies signed between BMY and many management level people at adxs from BMY I think this will be the company to watch for either bo or further deals
Bristol-Myers Squibb (BMY) released promising results for their cancer recurrence study involving keynote drug Opdivo.
The results showcased the checkpoint inhibiting drug outperforming Yervoy, also a Bristol-Myers drug, which surprised many, as top-line interim data was not expected until later in the trial. The study, titled CheckMate-238, examines cancer resurgence in 906 patients who had undergone complete resection,or removal, of Stage IIIb/c or Stage IV melanoma.
Checkpoint inhibitors are a line of drugs that block certain proteins made by immune system cells, such as T cells and certain cancer cells. Checkpoints help keep immune responses in check and are becoming widespread in the fight against cancer. Opdivo and Yervoy are both immuno-oncology agents and have similar functions, but differ with the proteins they target. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, while Yervoy binds to a protein receptor known as CTLA-4.
"[The announcement] is good news for patients and good news for Bristol-Myers, but one reason it's not a total game changer is because Bristol also has Yervoy," said Brad Loncar, an independent biotech investor who also manages his own Cancer Immunotherapy Index fund. "Yervoy is more toxic than Opdivo, so [Opdivo is] easier for patients to tolerate. Since Opdivo is more tolerable, they [Bristol] should be able to treat more patients."
"Those of us who have worked with immunotherapy for decades now have always had the belief that one of the reasons why immunotherapy should be effective is that the immune system has an exquisite specificity for recognizing subtle differences between antigens, between cells, and so forth that other types of therapy don't have, to more selectively target cancer cells without harming normal cells," said Jay Berzofsky, chief of the Vaccine Branch at the National Institute of Health's Center for Cancer Research.
Talking about the present where we stand at 6.50.
We are a year away from any approval.The movement of this stock price has had a daily tug downward.
Just changing the CEO alone will not help us .
We need to shed the shorts we need some favorable deals
Blue we are at 6 to talk about anything over 20 is pie in the sky
It will be interesting to see how DO trades his boat load of shares.
Maybe James can give us some insights into what happened
Maybe other tutes wanted in but demanded his removal.
If so we should see a sharp rise in short order
Down 9% after hours
The stock price speaks for itself concerning Dans execution.
I think it was one of the big pharma astra BMY or Amgen in concert with the tutes that appealed to the board to take him out.
Have a lawyer run a baby bio is like having a massage therapist give you anesthesia.Now let's get someone at the helm who can speak the nomenclature of the big pharm so we can elevate the value of the company!
Jumped on adxs three years ago and have been averaging down ever since.
Reading this board with various deal predictions and conference presentations that were going to elevate the stock.Still holding but would be insane to invest a single more centavo in this company!
fbg
you are looking for a 600% rise out of a stock that dropped 30% with no real news...
Hope you are right
The market isn't saying the same thing.
The best place to work
The worst place to invest
Raja the shining light at the end of the tunnel is the A train slamming us longs.....
We need change.!!!!!!!!!!!!!!!!!!!
Some healthy volumes on the up side today
Hope it's more than just a relief rally
Offer?
Did astra make us an offer?
Down over 30% in a week is that not real enough for you?
Astra did not agree to partner with us after our trials with them.
That's enough reflecting the data wasn't as positive as this board was led to believe.
Then there was no transparency from management just an ooops we are now partnering with BMY
If we were given the results of the trials with astra it would comfort me.
But with the info I can't help to think it was astra that walked away from us.
BMY would make a better partner
But would have liked to see BMY offer some inducement in the way of cash or taking 100% responsibility for costs.
The deal struck looks like it was done out of weakness on adxs part not that they were courted by BMY
The changing of dance partners is disconcerting
just last week adxs ran up 81 cents and then began to fall like a rock
Doc pitch is old and vision lost.
Time for new blood to steer the ship.
Either that or the science has been hyped i dont believe in the manipulator theories.
That's a real possibility
What's your take on the adxs astra relationship?
Something is missing???
Great results big pharma is aware
Stock price is in the shitter
What don't we know?
We don't know what we don't know
But it seems the shorts are all over us
Do they know something we don't?
We don't need fluff tomorrow.iI want the low stock price to be addressed for it's the elephant in the room.
Important article husk infection process is what causes 90% of diseases
Thanks for the article
Karma?
It's the stock price that's negative!
So when shorty covers the stock goes down?
LOOK AT THE VIDEO
THEN PEEK AT THE SP!!!!!!!!!!!!!!
there is an obvious disconnect here...
Strong partners,unique science,successful trials,large tutes invested in company.
Yet SP has no traction.
You cannot blame impatient stockholders for that!
Another dog and pony show to be held on Monday.My concern is the stock performance.It needs to be addressed by management after every positive statement.
Agreed but the big money will only come once they have locked up approval from EU
Why would a BP enter into a deal prior to receiving EU approval and run any risk?
we arent walking down we are sliding down quickly
Would like to see a strong finish today to determine if this is a harbinger of things to come
Up 9% today
Fry shorty s
Are we teamed with anyone in regard to the anal clinical trials?
The profit is in the treatment not the cure
In order to get FDA approval we do need partners like BMY so even though we get no monies up front it is a partner that will get us to the finish line.
Good job Dan!
Batermere
You nailed it!!!
Agreed they pointed to the fall season for trial updates.I didn't mean to imply anything more
Easy upon calling ir I was told the same thing time table you are relating to nothing going to happen till the fall.
If and when the stock takes off and raises we will give Dan the credit.
So why not lay some of the blame on him for the anemic stock price now.After all he has cut some failing deals.